Study on NTLA-2002 for Treating Hereditary Angioedema in Patients: Evaluating the Effects of Ziclumeran and Lonvoguran

3 1 1

What is this study about?

This clinical trial is focused on studying Hereditary Angioedema (HAE), a rare genetic condition that causes sudden swelling in various parts of the body. The study will evaluate a new treatment called NTLA-2002, which is a special type of medicine known as an advanced therapy medical product. This treatment involves a dispersion for infusion, which means it is given through a drip directly into the bloodstream. The active substances in NTLA-2002 are ziclumeran and lonvoguran, which are designed to target specific genetic components involved in HAE.

The purpose of the study is to assess how effective NTLA-2002 is in reducing the number of HAE attacks compared to a placebo. Participants in the study will receive either NTLA-2002 or a placebo through an intravenous infusion. The study will monitor participants over several weeks to see how the treatment affects the frequency and severity of their HAE attacks. The trial will also look at the overall quality of life for participants during the study period.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how well the treatment works. The study aims to provide valuable insights into the potential benefits of NTLA-2002 for people living with hereditary angioedema, offering hope for a new treatment option for this challenging condition.

1 run-in period

The run-in period lasts for 8 weeks. During this time, at least 2 hereditary angioedema (HAE) attacks must be documented by an investigator.

If 2 attacks occur within the first 28 days, randomization may occur after Day 28, provided all eligibility criteria are met.

2 randomization

Participants are randomly assigned to receive either the study medication NTLA-2002 or a placebo.

The study is double-blind, meaning neither the participant nor the investigator knows which treatment is being administered.

3 treatment administration

The study medication NTLA-2002 is administered via intravenous infusion.

The infusion is a dispersion, which means the medication is mixed in a liquid for administration.

4 primary observation period

This period lasts from Week 5 through Week 28.

The main objective is to evaluate the effectiveness of NTLA-2002 by measuring the number of HAE attacks compared to the placebo.

5 secondary observation period

During this time, the number of HAE attacks requiring on-demand treatment is recorded.

The severity of attacks and any changes in quality of life are also assessed.

6 end of study

The study is estimated to end on September 22, 2027.

Participants will have completed all required assessments and observations by this time.

Who Can Join the Study?

Participants must be at least 18 years old when they sign the consent form.
Participants must have a clinical history of HAE (Hereditary Angioedema), which involves repeated episodes of swelling under the skin or in the mucous membranes, without hives. They must also meet specific laboratory criteria related to C1-INH (C1 esterase inhibitor) levels.
Participants must have experienced at least 2 confirmed HAE attacks during an 8-week period before the study starts.
Participants must agree not to use long-term preventive treatments for HAE during the study period, unless it is confirmed safe by the study doctor.
Participants must have access to and be able to use medication to treat angioedema attacks when they occur.
Participants must meet certain laboratory test criteria, including liver function tests and kidney function tests.
Male participants with partners who can become pregnant must agree to use a condom during the study and for 4 months after the last study treatment.
Male participants must agree not to donate sperm during the study and for 4 months after the last study treatment.
Female participants who can become pregnant must use a highly effective method of birth control during the study and for 7 months after the last study treatment. This does not apply to women who are postmenopausal or have had certain surgeries that prevent pregnancy.
Female participants must agree not to undergo egg retrieval for in vitro fertilization during the study and for 7 months after the last study treatment.
Participants must be able to provide signed consent to participate in the study.
Participants must agree not to join another study that involves treatment during this study.

Who Cannot Join the Study?

Patients who do not have hereditary angioedema due to C1 esterase inhibitor deficiency (Type 1 or 2) cannot participate. Hereditary angioedema is a condition that causes sudden swelling, and C1 esterase inhibitor deficiency is a specific cause of this condition.
Patients who are not within the specified age range for the study cannot participate. The age range is not specified here, but it is important for eligibility.
Patients who are not part of the specified clinical trial group cannot participate. The specific group is not detailed here, but it is a requirement for the study.
Patients who are not male or female cannot participate, as the study includes both genders.
Patients who are not considered part of a vulnerable population cannot participate. A vulnerable population includes groups that may need special protection or consideration in research.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Medizinische Hochschule Hannover	Hanover	Germany
Centre Hospitalier Universitaire De Lille	Lille	France
CHU Grenoble Alpes	La Tronche	France

Other Sites

Site Name	City	Country
Hopital Saint Antoine	Paris	France
Charite Universitaetsmedizin Berlin KöR	Berlin	Germany
Acikfvvhe Uaq	Amsterdam	The Netherlands
Ahtijlhusv Pktbdgbl Hrzjyoxl Ds Mgkzpxtbl	Marseille	France
Gsrvoi Uccxbdlctd Fxmnibscl	Frankfurt	Germany

Trial status

Country	Status	Recruitment Start
France	Not recruiting	03.02.2025
Germany	Not recruiting	03.02.2025
The Netherlands	Not recruiting	03.02.2025

Trial locations

Investigated drugs:

NTLA-2002 is a medication being studied for its effectiveness in treating hereditary angioedema (HAE). This condition causes sudden and severe swelling in different parts of the body. The trial aims to see how well NTLA-2002 can reduce the number of HAE attacks over a specific period.

Investigated diseases:

Hereditary angioedema

Hereditary Angioedema due to C1 Esterase Inhibitor Deficiency (Type 1 or 2) – This is a genetic disorder characterized by recurrent episodes of severe swelling, known as angioedema. The swelling can affect various parts of the body, including the limbs, face, intestinal tract, and airway. It is caused by a deficiency or dysfunction of the C1 esterase inhibitor protein, which plays a role in regulating inflammation and fluid balance. During an attack, the swelling can be painful and may last for several days. The frequency and severity of attacks can vary widely among individuals. This condition is inherited in an autosomal dominant pattern, meaning a single copy of the altered gene in each cell is sufficient to cause the disorder.

Trial ID:

2024-515741-42-00

Protocol code:

ITL-2002-CL-301

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on NTLA-2002 for Treating Hereditary Angioedema in Patients: Evaluating the Effects of Ziclumeran and Lonvoguran

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?